Breaking News Instant updates and real-time market news.

MRK

Merck

$59.68

(0.00%)

04:55
05/15/18
05/15
04:55
05/15/18
04:55

Merck management to meet with Oppenheimer

Meeting to be held in New York on May 15 hosted by Oppenheimer.

  • 15

    May

  • 15

    May

  • 05

    Jun

  • 23

    Oct

MRK Merck
$59.68

(0.00%)

04/23/18
GSCO
04/23/18
UPGRADE
Target $73
GSCO
Conviction Buy
Goldman upgrades Merck to Buy, puts on Conviction List with $73 target
Goldman Sachs analyst Jami Rubin upgraded Merck to Buy from Neutral and added the shares to her firm's Conviction List. Rubin also upped her price target for the shares to $73 from $63. Merck closed Friday up 20c to $58.83. The analyst increased her estimates for Keytruda sales by $2B in 2021 and $4B in 2025. The narrative for Merck is "quickly changing with the success of Keytruda, driving a significant shift in product mix from a large primary care evolving into a specialty biopharma," Rubin tells investors in a research note. The analyst now sees "significant" margin upside from product mix shift with higher Keytruda sales than previously modeled. She believes Merck's operating margins could go from 32.5% in 2017 to 40% by 2025, with an inflection point beginning in the second half of 2018.
04/25/18
DBAB
04/25/18
NO CHANGE
DBAB
Hold
Merck may need to reassess animal health unit, says Deutsche Bank
While Merck (MRK) describes its animal health unit as a key growth driver and an important part of the company, it remains to be seen whether investors will continue to accept this as a reason for the business to remain within the company, Deutsche Bank analyst Gregg Gilbert tells investors in a research note. He believes the unit is potentially undervalued. Given Zoetis' (ZTS) success as a company and a stock, and Eli Lilly's (LLY) ongoing review of strategic options for its Elanco Animal Health business, Gilbert conducted a preliminary separation analysis of Merck's animal health unit. The analysis suggests that a separation could be meaningfully accretive to earnings. The analyst keeps a Hold rating on Merck.
04/26/18
BMOC
04/26/18
NO CHANGE
Target $70
BMOC
Outperform
Merck price target raised to $70 from $65 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Merck to $70 and kept his Outperform rating, forecasting a "mixed to net-positive" Q1 earnings report. The analyst notes the focus will likely fall on the core Keytruda and Januvia franchises as he raises his peak sales estimate for the former to $13B from $12B after KN-189 data, which he expects to be further supported by discussions at ASCO.
05/10/18
STFL
05/10/18
NO CHANGE
STFL
Hold
Exelixis pullback may create interesting entry point, says Stifel
After Exelixis (EXEL) and partner Roche (RHHBY) announced the Phase 3 IMblaze370 trial did not achieve statistical-significance on the primary efficacy endpoint evaluating the ability of a combination of a MEK inhibitor and anti-PD-L1 to improve overall survival in patients with microsatellite stable metastatic colorectal cancer, Stifel analyst Stephen Willey said he believes attrition in Exelixis shares might create an interesting entry point. The failure of IMblaze370 removes some of Exelixis' longer-term optionality and he expects topics of RCC growth/competition, label expansion, and longer-term cabozantinib exclusivity to remain core to the story going forward, said Willey who has a Hold rating on the stock. Array BioPharma (ARRY) also has Phase 1/2 development collaborations in place with both Bristol-Myers (BMY) and Merck (MRK) evaluating the MEK/PD-1 hypothesis in earlier-lines of MSS mCRC, noted Willey, who said he would "be opportunistic" on any weakness in its shares. He maintains a Buy rating on Array, which is down 5% in pre-market trading.

TODAY'S FREE FLY STORIES

TBK

Triumph Bancorp

$43.85

-0.3 (-0.68%)

09:04
09/20/18
09/20
09:04
09/20/18
09:04
Recommendations
Triumph Bancorp analyst commentary  »

DA Davidson raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

IMAX

Imax

$25.30

0.25 (1.00%)

09:04
09/20/18
09/20
09:04
09/20/18
09:04
Hot Stocks
Imax, Universal Pictures announce multi-year, multi-picture deal »

Universal Pictures and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

EDR

EdR

$41.49

(0.00%)

09:02
09/20/18
09/20
09:02
09/20/18
09:02
Hot Stocks
Breaking Hot Stocks news story on EdR »

Education Realty trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSC

Seven Stars Cloud Group

$4.40

0.02 (0.46%)

09:02
09/20/18
09/20
09:02
09/20/18
09:02
Hot Stocks
Ideanomics enters JV with APMEN Trade Tech Co »

Ideanomics is pleased to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALKS

Alkermes

$39.57

0.48 (1.23%)

09:01
09/20/18
09/20
09:01
09/20/18
09:01
Hot Stocks
FDA schedules Nov. 1 advisory committee to review Alkermes' MDD drug »

The Food and Drug…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

09:00
09/20/18
09/20
09:00
09/20/18
09:00
General news
The 3k initial claims drop »

The 3k initial claims…

09:00
09/20/18
09/20
09:00
09/20/18
09:00
General news
President Trump nominated Nellie Liang to the Federal Reserve Board »

President Trump nominated…

08:59
09/20/18
09/20
08:59
09/20/18
08:59
Conference/Events
The Federal Energy Regulatory Commission to hold a meeting »

Open Commission Meeting…

CCL

Carnival

$66.21

0.53 (0.81%)

08:56
09/20/18
09/20
08:56
09/20/18
08:56
Recommendations
Carnival analyst commentary  »

William Blair continues…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COWN

Cowen Group

$15.55

0.2 (1.30%)

08:55
09/20/18
09/20
08:55
09/20/18
08:55
Conference/Events
Cowen Group management to meet with Sandler O'Neill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 28

    Oct

BAC

Bank of America

$31.01

0.79 (2.61%)

, CRON

Cronos Group

$12.65

1.08 (9.33%)

08:55
09/20/18
09/20
08:55
09/20/18
08:55
Options
Notable open interest changes for September 20th »

Wednesday's total…

BAC

Bank of America

$31.01

0.79 (2.61%)

CRON

Cronos Group

$12.65

1.08 (9.33%)

GE

General Electric

$12.86

0.19 (1.50%)

FTV

Fortive

$85.99

-1.4 (-1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 23

    Sep

  • 25

    Sep

  • 25

    Sep

  • 27

    Sep

08:55
09/20/18
09/20
08:55
09/20/18
08:55
General news
FX Action: The dollar »

FX Action: The dollar was…

BLK

BlackRock

$483.50

11.365 (2.41%)

, CG

Carlyle Group

$23.45

-0.1 (-0.42%)

08:55
09/20/18
09/20
08:55
09/20/18
08:55
Conference/Events
Yahoo Finance to hold a summit »

All Markets Summit will…

BLK

BlackRock

$483.50

11.365 (2.41%)

CG

Carlyle Group

$23.45

-0.1 (-0.42%)

HD

Home Depot

$211.68

0.65 (0.31%)

Z

Zillow

$44.12

-0.49 (-1.10%)

BACHY

Bank of China

$0.00

(0.00%)

PYPL

PayPal

$89.31

-0.41 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 21

    Sep

  • 17

    Oct

  • 26

    Nov

NKE

Nike

$84.43

-0.86 (-1.01%)

08:53
09/20/18
09/20
08:53
09/20/18
08:53
Recommendations
Nike analyst commentary  »

Nike price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 25

    Sep

FLL

Full House Resorts

$2.83

(0.00%)

08:52
09/20/18
09/20
08:52
09/20/18
08:52
Initiation
Full House Resorts initiated  »

Full House Resorts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COWN

Cowen Group

$15.55

0.2 (1.30%)

08:51
09/20/18
09/20
08:51
09/20/18
08:51
Conference/Events
Cowen Group management to meet with JMP Securities »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 28

    Oct

CLAR

Clarus Corporation

$10.45

-0.35 (-3.24%)

08:50
09/20/18
09/20
08:50
09/20/18
08:50
Conference/Events
Clarus Corporation management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

08:50
09/20/18
09/20
08:50
09/20/18
08:50
General news
Treasury Action: yields remained elevated »

Treasury Action: yields…

ARKAY

Arkema

$0.00

(0.00%)

08:49
09/20/18
09/20
08:49
09/20/18
08:49
Conference/Events
Arkema management to meet with Morgan Stanley »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

NKE

Nike

$84.43

-0.86 (-1.01%)

08:49
09/20/18
09/20
08:49
09/20/18
08:49
Recommendations
Nike analyst commentary  »

Nike price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 25

    Sep

ATIS

Attis Industries

$0.27

0.0075 (2.88%)

08:48
09/20/18
09/20
08:48
09/20/18
08:48
Conference/Events
Attis Industries to host business update conference call »

Conference call to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

OSB

Norbord

$36.13

-1.95 (-5.12%)

, MERC

Mercer

$16.50

-0.45 (-2.65%)

08:47
09/20/18
09/20
08:47
09/20/18
08:47
Conference/Events
TD Securities to hold a conference »

North American Forest…

OSB

Norbord

$36.13

-1.95 (-5.12%)

MERC

Mercer

$16.50

-0.45 (-2.65%)

CCDBF

CCL Industries

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 27

    Sep

GALT

Galectin Therapeutics

$6.07

0.07 (1.17%)

, AMPE

Ampio

$0.50

-0.0198 (-3.82%)

08:47
09/20/18
09/20
08:47
09/20/18
08:47
Periodicals
STAT's Feuerstein calls this morning's Galectin data meaningless' »

STAT's Adam…

GALT

Galectin Therapeutics

$6.07

0.07 (1.17%)

AMPE

Ampio

$0.50

-0.0198 (-3.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRSP

Perspecta

$25.07

-0.63 (-2.45%)

08:46
09/20/18
09/20
08:46
09/20/18
08:46
Hot Stocks
Perspecta awarded $75M contract from Homeland Security »

Perspecta was awarded the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GT

Goodyear Tire

$24.29

0.245 (1.02%)

08:46
09/20/18
09/20
08:46
09/20/18
08:46
Hot Stocks
Goodyear Tire names Darren Wells as CFO, succeeding Laura Thompson »

The Goodyear Tire &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.